The Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona has identified a new genetic form of Alzheimer’s: the duplication of the APOE4 gene. This discovery highlights the importance of the APOE4 gene in Alzheimer’s research.
Biocross aims to position APOE4 as a reference biomarker for the risk/prognosis of diseases related to alterations in lipid metabolism (Alzeimer’s, cardiovascular diseases, Diabetes Mellitus Type II, pathologies that grow above the population average) and to identify and quantify this biomarker through its tests: e4Risk and e4Quant.
This discovery reinforces the need for specific preventive strategies and opens new perspectives for more personalized therapies in the future. It is an important step forward in the understanding and treatment of Alzheimer’s, highlighting the importance of continued research in the field of neurodegenerative diseases.
Published in the following media outlets:
- El País: “Identificada una nueva forma de alzhéimer genético presente en millones de personas”, 6 de mayo 2024.
- La Vanguardia: “Descubierta una nueva causa genética del alzheimer que afecta a un millón de personas en España”, 6 de mayo 2024.
- Onda Cero: “Un estudio identifica una nueva forma genética del alzhéimer que afecta a más del 2% de la población”, 6 de mayo 2024.
